Search Results for “brca” - Page 11 - Ovarian Cancer Research Alliance

Dec 22, 2014

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly...

Dec 11, 2017

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

...TILs, as well as BRCA 1 mutation carriers. BRCA 2 carriers were not observed to benefit from them. The study authors concluded, “that the extent of infiltration is prognostic, not...

Apr 14, 2015

Rucaparib Receives Breakthrough Therapy Designation from FDA

...of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough therapy” is a drug to...

Jun 29, 2021

What is Lynch Syndrome?

Inherited gene mutations, such as BRCA 1 and BRCA 2, can increase the risk of developing ovarian cancer as well as uterine (endometrial) cancer. Some of these mutations, which affect...

Feb 8, 2024

Ask the Experts | What Holds Promise in Ovarian Cancer Research?

...targeted treatment pathway at the time of diagnosis. The ability to determine germline and somatic mutations in BRCA and other BRCA-like genes can determine the best use of treatment strategies...

Oct 23, 2018

Maintenance olaparib Improves Progression-Free Survival in Phase III Clinical Trial

...BRCA 1 or 2 positive and newly diagnosed with an advanced stage of high grade serous or endometroid ovarian cancer, primary peritoneal, or fallopian tube cancer. Before starting olaparib, patients...

Mar 11, 2021

OCRA Awards Prizes in Ovarian Cancer Research

...for patients. Dr. Adams initial project, Development of Combination Therapy with PARP-inhibitors and Immunomodulation for BRCA-1 Epithelial Ovarian Cancer, explored a combination of PARP-inhibitor and immunotherapy to target CTLA-4 antibodies...

Mar 6, 2012

OCRF Invited to Participate in Important New National Research Initiative

...recommendations are published as “Recommendation Statements” and have formed the basis for clinical standards in medical practice. The USPSTF has launched a new initiative on Genetic Risk Assessment and BRCA Mutation...

Nov 22, 2022

Ovarian Cancer from Beyond the Ovary: Perspectives on Science, Clinical Progress and Advocacy

...doctors encouraging their patients with a BRCA mutation to undergo bilateral salpingectomy as a preventative measure for ovarian cancer. Dr. Miller took it a step further. “Dianne Miller was an...

Feb 7, 2025

Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research

...Investigators in honor of his work to advance knowledge of BRCA1-mutant ovarian cancer in order to overcome treatment resistance. A panel composed of select members of OCRA’s Scientific Advisory Committee...

Need to talk?

Free Genetic Testing Program

Harnessing AI for Early Detection

We Need Your Voice

Become a Monthly Donor

OCRA Joins Forces with Rivkin Center

Suggested Links

Quick Links

Suggested Links

Quick Links

Search Results for: "brca"

Search Again

FDA Approves Olaparib for Ovarian Cancer

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

Rucaparib Receives Breakthrough Therapy Designation from FDA

What is Lynch Syndrome?

Ask the Experts | What Holds Promise in Ovarian Cancer Research?

Maintenance olaparib Improves Progression-Free Survival in Phase III Clinical Trial

OCRA Awards Prizes in Ovarian Cancer Research

OCRF Invited to Participate in Important New National Research Initiative

Ovarian Cancer from Beyond the Ovary: Perspectives on Science, Clinical Progress and Advocacy

Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research

Stay Informed

Quick Links

About